Eli Lilly And Company · NYSE:LLY
Eli Lilly And — EASD 2026 Analyst Call
17 slides from Eli Lilly And's conference presentation, 2026
Slide 1: Not for promotional use
& Not for promotional use
Slide 2: 2026 Lilly EASD Analyst Call
2026 Lilly EASD Analyst Call
Slide 3: Agenda
Agenda Introduction Kenneth Custer, Ph.D., President, Cardiometabolic Health EASD 2026 Data Highlights Thomas Seck, M.D., Sr. Vice President, Product Development, Cardiomet Question & Answer Session Dan Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer Kenneth Custer, Ph.D., President, C
Slide 4: Safe Harbor Provision and Other Information
Safe Harbor Provision and Other Information This presentation contains forward -looking statements that are based on management's current expectations, but actual y differ results ma materially due to various factors. The company's results may be affected by factors including, but not limited andunc
Slide 5: 2026 Lilly EASD Highlights
2026 Lilly EASD Highlights Market -Leading Portfolio Raising the Bar with Foundayo, Retatrutide EloraTZP & #1 prescribed medicine for obesity Foundayo demonstrated cardiovascular safety and sustained glycemic control and weight loss in ACHIEVE -4 #1 prescribed incretin for type 2 diabetes Retatrutid
Slide 6: Foundayo ACHIEVE-4
Foundayo ACHIEVE -4 2026 Lilly EASD Analyst Call Not for promotional use 6
Slide 7: Foundayo ACHIEVE-4 Results
Foundayo ACHIEVE -4 Results Key Highlights: ACHIEVE-4 Select Hazard Ratios (95% CI) Demonstrated cardiovascular saf and sustained A1C reduction and of MACE-41 Timetofirstoccurrence 0.84 (0.59– 1.20)2 weight loss 16% lower risk of MACE 4 -4 events -31 Time to first occurrence of MACE 0.77 (0.52– 1.13
Slide 8: Retatrutide TRIUMPH-2
Retatrutide TRIUMPH-2 2026 Lilly EASD Analyst Call Not for promotional use 8
Slide 9: TRIUMPH-2 Weight Change and HbA1c Results
TRIUMPH -2 Weight Change and HbA1c Results Participants with Overweight or Obesity and T2D 1 (106.4 kg) Percent Change from Baseline Body Weight 1 (7.7%) Percent Change from Baseline HbA1c Weeks Weeks 0 4 8 12 16 20 24 36 52 68 80 EE 0 4 8 12 16 24 36 52 68 80 EE 0 0.0 Change From Baseline Change Fr
Slide 10: TRIUMPH-2 Safety & Tolerability
TRIUMPH -2 Safety & Tolerability Key Highlights: Treatment Emergent Retatrutide Retatrutide Retatrutide Placebo Adverse Events (%) 4 mg 9 mg 12 mg GI AEs were the most common Diarrhea 13% 27% 33% 34% reason for discontinuation Nausea 8% 14% 21% 28% Constipation 9% 14% 16% 17% Dysesthesia and urinary
Slide 11: EloraTZP Phase 2 Results
EloraTZP Phase 2 Results 2026 Lilly EASD Analyst Call Not for promotional use 11
Slide 12: EloraTZP Phase 2 Weight Loss
EloraTZPPhase 2 Weight Loss Participants with Overweight or Obesity and T2D 1 (105.4 kg) Percent Change from Baseline Body Weight Key Highlights: Weeks 0 4 8 12 16 20 24 36 48 EE EloraTZPcombination activates 0 three complementary nutrient - -3.0% Placebo stimulating hormones Change From Baseline -5
Slide 13: EloraTZP Phase 2 HbA1c
EloraTZPPhase 2 HbA1c Participants with Overweight or Obesity and T2D 1 (8.1%) Change from Baseline HbA1c Key Highlights: Weeks 0 12 24 36 48 EE Eloralintide and EloraTZPdelivered 0 clinically meaningful A1C control -0.29% Placebo Change From Baseline -1 EloraTZPimproved A1C by 2.9% at -1.06% Elora
Slide 14: EloraTZP Safety & Tolerability
EloraTZPSafety & Tolerability Eloralintide EloraTZP TZP Treatment Emergent 1/3 mg 3/6/9 mg 1 Placebo 1/3 mg 3/6/9 mg 15 mg Adverse Events (%) +5 mg +15 mg Nausea 11% 14% 16% 14% 49% 26% Diarrhea 19% 24% 18% 19% 30% 23% Constipation 8% - 13% 22% 14% 20% Fatigue 8% 5% 11% 17% 24% 14% Decreased appetit
Slide 15: Eloralintide & EloraTZP Global Obesity Development Programs
EloralintideEloraTZP & Global Obesity Development Programs Key Highlights: ENLIGHTEN-1: vs. placebo, without T2D ENLIGHTEN-2: vs. placebo, with T2D Eloralintide is a unique-incretin non option with potential for favorab ENLIGHTEN-3: vs. placebo, with obstructive sleep apnea weight loss and tolerabil
Slide 16: Building for Sustained Leadership
Building for Sustained Leadership PROVEN MEDICINES ESTABLISHED AND MOST PRESCRIBED INCRETIN THERAPIES AN EFFECTIVE ORAL NOW SMALL MOLECULE TO TREAT OBESITY AT SCALE SELECTIVE AMYLIN, Eloralintide, Retatrutide, NEW FRONTIERS TRIPLE AGONISM EloraTZP,& Next Generation Medicines 2026 Lilly EASD Analyst
Slide 17: Trademarks
Trademarks All trademarks and trade names referred to in this presentation are the property of the company, or, to the or trade extentnames trademarks belonging to other companies are referenced in this presentation, the property of their respective owners. ence,Solely the trademarks for conveniand